R P Piggott1, P S Waters2, M J Kerin2. 1. Department of Surgery, Galway University Hospital, Galway, Ireland. robpiggott1@gmail.com. 2. Department of Surgery, Galway University Hospital, Galway, Ireland.
Abstract
BACKGROUND: Tumour metastatic disease reflects a complex interplay between tumour characteristics and local host factors. This complex relationship may have an influence on the development of metastatic disease and patient survival. Multiple factors of the primary tumour influence the development of metastases and survival in patients. Breast cancer subtype has been shown to influence patient prognosis and response to therapy. AIM: The aim of our study was to correlate breast cancer subtype with bony metastatic disease and patient survival. METHODS: All women undergoing breast cancer surgery in a single institution in Ireland between January 1990 and July 2012 were included in the study. A prospectively maintained database was reviewed and expanded retrospectively. Univariate and multivariate analysis was carried out. RESULTS: Database interrogation identified 238 patients for inclusion. Patient demographics, tumour characteristics and survival data were analyzed. Average follow-up of patients was 57.6 months (range 1-272 months). Multivariate analysis identified oestrogen receptor positivity and presence of metastatic disease elsewhere as significant factors influencing the development of bone metastases. Breast cancer subtype did not influence the bone metastases development (p = 0.99). Breast cancer subtype influenced patients' overall survival (p < 0.001), bone disease-free survival (p < 0.001) and survival with bone disease (p < 0.001). Subtype did not influence distant disease-free survival. CONCLUSION: Breast cancer subtype influences patients' overall survival, with luminal A and B subtypes associated with the best outcome. Bone metastases remain the most common form of breast cancer metastases but are not influenced by breast cancer subtype.
BACKGROUND:Tumour metastatic disease reflects a complex interplay between tumour characteristics and local host factors. This complex relationship may have an influence on the development of metastatic disease and patient survival. Multiple factors of the primary tumour influence the development of metastases and survival in patients. Breast cancer subtype has been shown to influence patient prognosis and response to therapy. AIM: The aim of our study was to correlate breast cancer subtype with bony metastatic disease and patient survival. METHODS: All women undergoing breast cancer surgery in a single institution in Ireland between January 1990 and July 2012 were included in the study. A prospectively maintained database was reviewed and expanded retrospectively. Univariate and multivariate analysis was carried out. RESULTS: Database interrogation identified 238 patients for inclusion. Patient demographics, tumour characteristics and survival data were analyzed. Average follow-up of patients was 57.6 months (range 1-272 months). Multivariate analysis identified oestrogen receptor positivity and presence of metastatic disease elsewhere as significant factors influencing the development of bone metastases. Breast cancer subtype did not influence the bone metastases development (p = 0.99). Breast cancer subtype influenced patients' overall survival (p < 0.001), bone disease-free survival (p < 0.001) and survival with bone disease (p < 0.001). Subtype did not influence distant disease-free survival. CONCLUSION:Breast cancer subtype influences patients' overall survival, with luminal A and B subtypes associated with the best outcome. Bone metastases remain the most common form of breast cancer metastases but are not influenced by breast cancer subtype.
Entities:
Keywords:
Breast cancer; Breast cancer survival; Metastases; Metastatic bone disease; Molecular subtype
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Marcel Smid; Yixin Wang; Yi Zhang; Anieta M Sieuwerts; Jack Yu; Jan G M Klijn; John A Foekens; John W M Martens Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Rebecca Dent; Wedad M Hanna; Maureen Trudeau; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Breast Cancer Res Treat Date: 2008-06-10 Impact factor: 4.872
Authors: Otto Metzger-Filho; Zhuoxin Sun; Giuseppe Viale; Karen N Price; Diana Crivellari; Raymond D Snyder; Richard D Gelber; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch; Fatima Cardoso Journal: J Clin Oncol Date: 2013-07-29 Impact factor: 44.544
Authors: Jae Myoung Noh; Doo Ho Choi; Seung Jae Huh; Won Park; Jung Hyun Yang; Seok Jin Nam; Young Hyuck Im; Jin Seok Ahn Journal: J Breast Cancer Date: 2011-03-31 Impact factor: 3.588
Authors: Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein Journal: Proc Natl Acad Sci U S A Date: 2003-06-26 Impact factor: 12.779
Authors: Yao Xu; Haixiao Wu; Guijun Xu; Zhuming Yin; Xin Wang; Vladimir P Chekhonin; Karl Peltzer; Shu Li; Huiyang Li; Jin Zhang; Wenjuan Ma; Chao Zhang Journal: Breast J Date: 2022-01-31 Impact factor: 2.269
Authors: Margaret L Hankins; Clair N Smith; Beverly Hersh; Tanya Heim; Rebekah Belayneh; Sean Dooley; Adrian V Lee; Steffi Oesterreich; Peter C Lucas; Shannon L Puhalla; Kurt R Weiss; Rebecca J Watters Journal: J Bone Oncol Date: 2021-05-03 Impact factor: 4.072